genesis, it has been suggested that plaque hypoxia be used as a target for molecular imaging to identify high-risk patients, anticipate acute cardiovascular events, and monitor atheroma therapies (1) .
We demonstrate the potential of hypoxia imaging in humans using a highly selective hypoxia marker, 18 F-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol (HX4), for positron emission tomography/computed tomography (PET/ CT) (2) .
In 8 patients with carotid artery stenosis, we performed multimodal imaging within 3 weeks, consisting of: 1) magnetic resonance imaging (MRI) with a 3.0-T whole-body scanner (Intera, Philips, Best, the Netherlands) to calculate the normalized wall index (mean wall area/outer wall area) (3); 2) 18 F-fluorodeoxyglucose (FDG)-PET/CT (100 MBq); and 3) HX4-PET/CT (100 MBq) imaging on a dedicated scanner (Gemini, Philips) 90 min after tracer infusion.
FDG and HX4 uptake was quantified in the carotid . 
